Pharmaceutical and biotechnology major Wockhardt Ltd reported a sharp turnaround in Q4FY26, posting a net profit of ₹164 crore compared to a net loss of ₹45 crore in the same period last year, driven by robust growth across biotech and international markets.
Revenue for the quarter rose 30% year-on-year to ₹965 crore from ₹743 crore, while EBITDA surged 147% to ₹196 crore, reflecting improved operating leverage.
FY26: Profitability restored, margins expand
For the full year, Wockhardt reported revenue of ₹3,373 crore, up 11% from ₹3,033 crore in FY25. EBITDA grew 51% to ₹630 crore, while the company posted a net profit of ₹199 crore, reversing a net loss of ₹57 crore in the previous fiscal.
Biotech business emerges as key growth engine
The company’s biotech operations delivered standout performance, with Q4 revenue rising 126% to ₹252 crore. For FY26, biotech revenue grew 27% to ₹697 crore.
Growth was led by the emerging markets biotech segment, which expanded over 34% during the year, supported by new partnerships and deal wins in markets such as Thailand, Egypt, Algeria, and Latin America. The India biotech business also maintained double-digit growth momentum.
Wockhardt said upcoming launches of insulin analogs are expected to unlock significant opportunities, reinforcing its position in diabetes care.
India, UK and emerging markets show traction
The India branded business grew 18% in Q4 to ₹112 crore and 15% for FY26 to ₹523 crore, supported by strong performance in diabetic therapies, NCE (EMROK), and the regenerative derma segment.
The UK business reported revenue of ₹349 crore in Q4, up 20%, while full-year revenue rose 13% to ₹1,318 crore.
Emerging markets delivered the strongest growth, with Q4 revenue surging 124% to ₹320 crore and FY26 revenue rising 35% to ₹958 crore, largely driven by the biotech insulin portfolio and strong traction in Latin America.
The Ireland business also posted steady growth, with Q4 revenue up 12% to ₹52 crore and FY26 revenue increasing 16% to ₹209 crore.
Exceptional items impact reported numbers
During the quarter, the company reported exceptional items of ₹85 crore, including one-time charges related to restructuring, regulatory compliance, and liquidation of a US entity.
A settlement with a Chapter 7 trustee resulted in a net charge of ₹12.7 crore. Additionally, a settlement agreement with Dr. Reddy’s Laboratories led to a credit of ₹35.35 crore, recorded under exceptional items.